leon-nanodrugs GmbH has announced a series of significant developments, closing an oversubscribed financing round whilst appointing two senior scientific leaders, as the Munich-based company accelerates its transition into full commercial deployment of its GMP-compatible nanoparticle manufacturing platform.

Financing round to fund global commercial expansion

The oversubscribed round, which drew participation from both existing and new investors, will fund the market launch of LEON’s NANO® systems and support global commercial expansion to meet growing demand from pharmaceutical and biotechnology companies for scalable, reproducible nanoparticle production technologies.

“The financing gives us the momentum to scale our commercial footprint, support our partners globally, and continue advancing a manufacturing platform designed for the next generation of therapeutics,” said Christian Nafe, CFO of LEON.

Dr Frank Mühlenbeck, Managing Partner at LBBW Venture Capital and Chairman of LEON’s Supervisory Board, commented that the company is “well positioned to emerge as a leader in scalable nanoparticle manufacturing,” citing market-ready systems and growing customer demand.

Dr Matthias Schumacher the new Chief Technology Officer, and Dr Blerina Shkodra, the new Chief Scientific Officer at leon-nanodrugs.

Addressing a critical manufacturing bottleneck

At the core of LEON’s platform is its proprietary FR-JET® mixing technology, which enables robust scale-up without process redesign, reducing operational risk and maintaining consistent product quality across small-batch, rapid-turnaround, and GMP-scale settings. RNA-based medicines, cancer vaccines, and cell and gene therapies all place exacting demands on nanoparticle production reproducibility — requirements that conventional manufacturing approaches have struggled to meet consistently.

New CSO and CTO appointed to strengthen scientific and engineering leadership

Alongside the financing announcement, LEON has appointed Dr Blerina Shkodra as Chief Scientific Officer (CSO) and Dr Matthias Schumacher as Chief Technology Officer (CTO). The appointments bring a complementary combination of formulation science and advanced engineering expertise to the executive team. Dr Shkodra, who has held senior scientific leadership roles within LEON for several years, will direct the company’s scientific strategy with a focus on formulation science and application development across emerging therapeutic modalities, including RNA-based therapeutics, cancer vaccines, and cell and gene therapies. Her expertise in nanoparticle formulation and translational development is expected to support LEON’s efforts to deliver rapid, reproducible encapsulation processes across a broad range of payloads and indications.

Dr Schumacher, who led the development of LEON’s FR-JET platform, brings both scientific and engineering expertise to his new role. As CTO, he will oversee expansion of the company’s technology and equipment portfolio, focusing on the integration of LEON’s systems into global biopharma R&D and supply chains for advanced therapeutics and RNA-based medicines.

“These appointments mark an important step as LEON moves into full commercial deployment,” said Dr Wolfgang Hofmann, Chief Executive Officer at LEON. “Strengthening our scientific and technological leadership supports our long-term vision of enabling flexible and scalable nanoparticle manufacturing.”

Taken together, the financing and leadership appointments signal a period of accelerated commercial and organisational development for LEON as demand for fit-for-purpose nanoparticle manufacturing continues to grow across the advanced therapeutics sector.

For more information, visit: https://leon-nanodrugs.com